PHT Corp. Appoints Stanley Erck President and
Chief Executive Officer
Former President and CEO of Procept to Lead Emerging Innovator of
Clinical Trial Direct Data Capture Technologies
BOSTON--(BUSINESS WIRE)--May 25, 1999-- PHT Corp., an emerging growth company and the leading developer of
web-based clinical trial direct data capture and management technologies, today announced the appointment of Stanley Erck to
the position of President and Chief Executive Officer. Erck brings more than 20 years of experience in corporate healthcare
development and marketing to PHT Corp., and was previously president and CEO of Procept, Inc., a development stage
biopharmaceutical company based in Cambridge, Mass.
Erck joins PHT at a time when the Company is preparing to launch open system technologies that will revolutionize the conduct
of pharmaceutical, biotech and medical device clinical trials and also help shape their statistical outcome.
Working closely with co-founders Stephen Raymond, Ph.D. and Geoff Gordon, and Chief Operating Officer James Becker,
Erck is focusing on establishing strategic business partnerships, broadening PHT's network of support in the financial
community and guiding the development of infrastructure to support the growing software development, sales, administration
and client service functions.
''We are excited to welcome a chief executive of Stan's caliber and industry experience to our senior management team,'' said
Stephen Raymond, co-founder, chairman and chief scientist of PHT. ''His in-depth understanding of the needs of the
biopharmaceutical industry coupled with hands-on experience with the dynamics of an emerging growth company will be major
assets to PHT as we move forward into this critical next stage of new product introductions and commercialization.''
PHT's technology enables clinical trial participants to directly provide clinical researchers with a ''real-time'' paperless flow of
information describing their experience with an experimental device or medicine. Right now, study participants typically provide
written diary information or report to a clinical trial site for monitoring at intervals of weeks or even months.
This sporadic system yields low quality patient data and is time-consuming because manually prepared information must pass
through intermediary layers of study support staff before reaching the research scientist.
''PHT has developed a technology that is quite unique and will transform a drug development process that takes too much
time, uses too much paper and is excessively labor intensive,'' said Erck. ''Perhaps the most significant benefit of PHT's
solution is the impact it can have on improving the quality of the data resulting in better medicine.''
At Procept, which develops therapeutics designed to treat autoimmune diseases, organ transplant rejections and infectious
diseases, Erck secured $100 million in financial support from prominent venture capitalists, an IPO and subsequent public
financing, and from corporate partnerships and was responsible for the development of drug candidates in the US and Europe.
Erck holds a Bachelor of Science degree in Finance/Economics from the University of Illinois and an MBA from the University
of Chicago.
About PHT Corp.
PHT Corp. is a leading provider of web-based clinical trial direct data capture and management technologies designed to
support the development of better medicine by improving the quality of data evaluated in clinical trials. Major pharmaceutical
companies are using PHT's technology to accelerate their clinical trial process and retrieve patient data on a ''real-time'' basis.
The Company is headquartered in Boston and can be found on the Web at www.phtcorp.com |
